161 related articles for article (PubMed ID: 32687165)
1. CRISPR/Cas9 treatment causes extended TP53-dependent cell cycle arrest in human cells.
Geisinger JM; Stearns T
Nucleic Acids Res; 2020 Sep; 48(16):9067-9081. PubMed ID: 32687165
[TBL] [Abstract][Full Text] [Related]
2. CRISPR screens are feasible in TP53 wild-type cells.
Brown KR; Mair B; Soste M; Moffat J
Mol Syst Biol; 2019 Aug; 15(8):e8679. PubMed ID: 31464370
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Editing of the
Mirgayazova R; Khadiullina R; Chasov V; Mingaleeva R; Miftakhova R; Rizvanov A; Bulatov E
Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32630614
[TBL] [Abstract][Full Text] [Related]
4. CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response.
Haapaniemi E; Botla S; Persson J; Schmierer B; Taipale J
Nat Med; 2018 Jul; 24(7):927-930. PubMed ID: 29892067
[TBL] [Abstract][Full Text] [Related]
5. Parallel CRISPR-Cas9 screens clarify impacts of p53 on screen performance.
Bowden AR; Morales-Juarez DA; Sczaniecka-Clift M; Agudo MM; Lukashchuk N; Thomas JC; Jackson SP
Elife; 2020 May; 9():. PubMed ID: 32441252
[TBL] [Abstract][Full Text] [Related]
6. CRISPR-Cas9 fusion to dominant-negative 53BP1 enhances HDR and inhibits NHEJ specifically at Cas9 target sites.
Jayavaradhan R; Pillis DM; Goodman M; Zhang F; Zhang Y; Andreassen PR; Malik P
Nat Commun; 2019 Jun; 10(1):2866. PubMed ID: 31253785
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
Tadić V; Josipović G; Zoldoš V; Vojta A
Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the CRISPR/Cas9 directed mutant TP53 gene repairing effect in human prostate cancer cell line PC-3.
Batır MB; Şahin E; Çam FS
Mol Biol Rep; 2019 Dec; 46(6):6471-6484. PubMed ID: 31571107
[TBL] [Abstract][Full Text] [Related]
9. Generation and characterization of three CRISPR/Cas9 edited RB1 null hiPSC lines for retinoblastoma disease modelling.
Agrawal T; Maddileti S; Mariappan I
Stem Cell Res; 2024 Apr; 76():103373. PubMed ID: 38452707
[TBL] [Abstract][Full Text] [Related]
10. Nuclear Envelope Rupture Is Enhanced by Loss of p53 or Rb.
Yang Z; Maciejowski J; de Lange T
Mol Cancer Res; 2017 Nov; 15(11):1579-1586. PubMed ID: 28811362
[TBL] [Abstract][Full Text] [Related]
11. Rapid genome editing by CRISPR-Cas9-POLD3 fusion.
Reint G; Li Z; Labun K; Keskitalo S; Soppa I; Mamia K; Tolo E; Szymanska M; Meza-Zepeda LA; Lorenz S; Cieslar-Pobuda A; Hu X; Bordin DL; Staerk J; Valen E; Schmierer B; Varjosalo M; Taipale J; Haapaniemi E
Elife; 2021 Dec; 10():. PubMed ID: 34898428
[TBL] [Abstract][Full Text] [Related]
12. DYRK1A regulates the recruitment of 53BP1 to the sites of DNA damage in part through interaction with RNF169.
Menon VR; Ananthapadmanabhan V; Swanson S; Saini S; Sesay F; Yakovlev V; Florens L; DeCaprio JA; Washburn MP; Dozmorov M; Litovchick L
Cell Cycle; 2019 Mar; 18(5):531-551. PubMed ID: 30773093
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of 53BP1 favors homology-dependent DNA repair and increases CRISPR-Cas9 genome-editing efficiency.
Canny MD; Moatti N; Wan LCK; Fradet-Turcotte A; Krasner D; Mateos-Gomez PA; Zimmermann M; Orthwein A; Juang YC; Zhang W; Noordermeer SM; Seclen E; Wilson MD; Vorobyov A; Munro M; Ernst A; Ng TF; Cho T; Cannon PM; Sidhu SS; Sicheri F; Durocher D
Nat Biotechnol; 2018 Jan; 36(1):95-102. PubMed ID: 29176614
[TBL] [Abstract][Full Text] [Related]
14. Restoring the p53 'Guardian' Phenotype in p53-Deficient Tumor Cells with CRISPR/Cas9.
Chira S; Gulei D; Hajitou A; Berindan-Neagoe I
Trends Biotechnol; 2018 Jul; 36(7):653-660. PubMed ID: 29478674
[TBL] [Abstract][Full Text] [Related]
15. 53BP1 and USP28 mediate p53 activation and G1 arrest after centrosome loss or extended mitotic duration.
Meitinger F; Anzola JV; Kaulich M; Richardson A; Stender JD; Benner C; Glass CK; Dowdy SF; Desai A; Shiau AK; Oegema K
J Cell Biol; 2016 Jul; 214(2):155-66. PubMed ID: 27432897
[TBL] [Abstract][Full Text] [Related]
16. Cas9 activates the p53 pathway and selects for p53-inactivating mutations.
Enache OM; Rendo V; Abdusamad M; Lam D; Davison D; Pal S; Currimjee N; Hess J; Pantel S; Nag A; Thorner AR; Doench JG; Vazquez F; Beroukhim R; Golub TR; Ben-David U
Nat Genet; 2020 Jul; 52(7):662-668. PubMed ID: 32424350
[TBL] [Abstract][Full Text] [Related]
17. The RASSF6 Tumor Suppressor Protein Regulates Apoptosis and Cell Cycle Progression via Retinoblastoma Protein.
Hossain S; Iwasa H; Sarkar A; Maruyama J; Arimoto-Matsuzaki K; Hata Y
Mol Cell Biol; 2018 Sep; 38(17):. PubMed ID: 29891515
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of RB1, CDKN2A, and TP53 have distinct effects on genomic stability at side-by-side comparison in karyotypically normal cells.
Andersson N; Saba KH; Magnusson L; Nilsson J; Karlsson J; Nord KH; Gisselsson D
Genes Chromosomes Cancer; 2023 Feb; 62(2):93-100. PubMed ID: 36124964
[TBL] [Abstract][Full Text] [Related]
19. Modeling Breast Cancer Using CRISPR-Cas9-Mediated Engineering of Human Breast Organoids.
Dekkers JF; Whittle JR; Vaillant F; Chen HR; Dawson C; Liu K; Geurts MH; Herold MJ; Clevers H; Lindeman GJ; Visvader JE
J Natl Cancer Inst; 2020 May; 112(5):540-544. PubMed ID: 31589320
[TBL] [Abstract][Full Text] [Related]
20. Cell cycle arrest and p53 prevent ON-target megabase-scale rearrangements induced by CRISPR-Cas9.
Cullot G; Boutin J; Fayet S; Prat F; Rosier J; Cappellen D; Lamrissi I; Pennamen P; Bouron J; Amintas S; Thibault C; Moranvillier I; Laharanne E; Merlio JP; Guyonnet-Duperat V; Blouin JM; Richard E; Dabernat S; Moreau-Gaudry F; Bedel A
Nat Commun; 2023 Jul; 14(1):4072. PubMed ID: 37429857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
